Fig. 2From: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trialPatients with BRCA1- or BRCA2-mutated HER2-negative, advanced breast cancer will be randomized to carboplatin-olaparib (based on the Part 1 results) or capecitabine. After progression on first line, patients will be administered physician’s best choice out of capecitabine, paclitaxel, vinorelbine, or eribulin to assess progression-free survival on second line treatment. For patients who were not randomized to olaparib, a rollover protocol is available for third line treatment in the advanced settingBack to article page